PMID- 10025826
OWN - NLM
STAT- MEDLINE
DCOM- 19990305
LR  - 20161124
IS  - 0161-5505 (Print)
IS  - 0161-5505 (Linking)
VI  - 40
IP  - 2
DP  - 1999 Feb
TI  - Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in 
      patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting 
      enzyme inhibitor therapy.
PG  - 217-23
AB  - Impaired cardiac sympathetic activity can be evaluated by 
      123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance 
      of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy 
      (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 
      mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) 
      inhibitors. Patients were studied before treatment, after 5 mo of treatment (only 
      in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the 
      heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from 
      anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer 
      injection. New York Heart Association (NYHA) class and left ventricular ejection 
      fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS 
      decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 
      0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both 
      groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 
      0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M 
      were more improved in group A than in group B (P < 0.05). LVEF was significantly 
      increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). 
      NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 
      0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group 
      A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac 
      sympathetic activity evaluated by MIBG images improved after the beta-blocker 
      therapy more than with the treatment that used ACE inhibitors.
FAU - Toyama, T
AU  - Toyama T
AD  - Second Department of Internal Medicine, Gunma University School of Medicine, 
      Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
FAU - Aihara, Y
AU  - Aihara Y
FAU - Iwasaki, T
AU  - Iwasaki T
FAU - Hasegawa, A
AU  - Hasegawa A
FAU - Suzuki, T
AU  - Suzuki T
FAU - Nagai, R
AU  - Nagai R
FAU - Endo, K
AU  - Endo K
FAU - Hoshizaki, H
AU  - Hoshizaki H
FAU - Oshima, S
AU  - Oshima S
FAU - Taniguchi, K
AU  - Taniguchi K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Thallium Radioisotopes)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - *3-Iodobenzylguanidine
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Cardiomyopathy, Dilated/diagnostic imaging/drug therapy/*physiopathology
MH  - Echocardiography
MH  - Female
MH  - Heart/diagnostic imaging/*innervation
MH  - Humans
MH  - Male
MH  - Metoprolol/therapeutic use
MH  - Middle Aged
MH  - *Radiopharmaceuticals
MH  - Stroke Volume
MH  - Sympathetic Nervous System/*physiopathology
MH  - Thallium Radioisotopes
MH  - Tomography, Emission-Computed, Single-Photon
EDAT- 1999/02/20 00:00
MHDA- 1999/02/20 00:01
CRDT- 1999/02/20 00:00
PHST- 1999/02/20 00:00 [pubmed]
PHST- 1999/02/20 00:01 [medline]
PHST- 1999/02/20 00:00 [entrez]
PST - ppublish
SO  - J Nucl Med. 1999 Feb;40(2):217-23.